Canal D
Wednesday, May 12, 2004: 2:00 PM-3:30 PM

D11: Adverse Events Associated with Anthrax Vaccine: A Report from the Anthrax Vaccine and Antibiotic Availability Program and the Role of the Vaccine Analytic Unit

In 1999, Congress directed CDC to conduct research on the safety and efficacy of current anthrax vaccine. In response, CDC is conducting a wide range of safety activities that indirectly provide support for current and future biodefense vaccines administered in military and civilian settings. The CDC’s Anthrax Vaccine and Antibiotic Availability Program (AVAAP) was implemented to provide additional post exposure prophylaxis for individuals potentially exposed to B. anthracis in Fall 2001. The new Vaccine Analytic Unit conducts vaccine safety research using the Defense Medical Surveillance System database.
Learning Objectives: After attending this session, participants should be able to describe CDC’s anthrax vaccine research.

Moderator:Michael M. McNeil
2:00 PM5628Introductory Remarks
2:15 PM5630Presentation — Michael McNeil
2:30 PM5631Presentation — Stacey Martin
2:45 PM5632Presentation — Daniel Payne
3:00 PM5633Presentation — Charles Rose
3:15 PM5629Discussion

The 38th National Immunization Conference of CDC